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A BSTRA CT. 6 -mercaptopurine (6MP) cytotoxicity is caused by thioguanine and methylthioinosine nucleo­
tides. Thiopurine méthylation occurs to a large extent in vivo and in vitro. In this reaction, S-adenosyl-L- 
methionine (AdoMet), produced from methionine and ATP, is converted into S-adenusy l-L-htunocysreine 
(AdoHcy) which, in turn, is hydrolyzed into homocysteine. Remethylation of homocysteine into methionine is 
inhibited by methotrexate (MTX). In cultured lymphoblasts, AdoMenAdoHcy ratio and DNA méthylation 
decrease after incubation with 6MP. The aim of the present study was to investigate the influence of high-do.se 
6MP on the méthylation capacity in children with acute lymphoblastic leukemia.
Five patients received 4 courses with high-dose intravenous MTX (5 g • m in 24 hr) immediately followed 
by high-dose 6MP (1300 mg • m~2 in 24 hr). Five control patients received high-dose MTX and oral 6MP (25 
mg • m~2 daily for 8 weeks). Leucovorin rescue was started at .36 hr in both groups.
In the intravenous 6MP group, 6-methylmercaptopurine, its riboside, and 6-methylmercapto-8-hydroxypurine 
were detectable in plasma in concentrations of 0.3-2.6 |jlM (6MP steady state levels: 11.6 (xM). In red blood 
cells, mean methylthioinosine nucleotide levels were one third of those of ATP (13,1 nmol/10”). AdoHcy levels 
(10 pmol/108) remained constant in both groups and AdoMet was not detectable (<20 pmol/10,s). In both 
groups, plasma homocysteine increased and methionine decreased following administration of MTX. The delay 
in the recovery of methionine in the intravenous 6MP group after MTX infusion is probably the result- of an 
increased demand on methyl groups during 6MP infusion. BIOCHKM PHARMACOL 51;9:1165-1171,
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§ is used in the treatment of ALL. It has no intrinsic
cytotoxic activity, but is converted into active metabolites 
intracellularly (Scheme 1). 6MP
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ferase (EC 2.1.1.67) (TPMT). The TPMT activity is con­
trolled by a genetic polymorphism and the activity in RBC 
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lets, liver, and ki
10
7]. Population studies showed that
I  ■ '
•'V ** % oi
in cytotoxicity in vitro, ei­
ther by incorporation of thioguanine nucleotides into DNA 
and RNA [1,2] or by inhibition of purine de novo synthesis 
by MetlMP [2, 3]. 6MP is methylated into MeMP and 6MP- 
riboside into MeMPR (Scheme 1). The thiopurine meth-
the frequency distribution is trimodal with 
subjects displaying high activity, 11.1% intermediate activ­
ity, and 1 out of 300 subjects having undeteetahle TPMT
. Thiopurine méthylation requires AdoMet as
onor [9]. AdoMet is the universal methyldonor for 
many methyltransferase reactions of small molecules, DNA,
ylation reactions are catalyzed by thiopurine methyltrans- RNA, proteins, and phospholipids, and plays an important
role in the regulation of the action of these compounds [10]. 
Scheme 2 shows the transmethylation pathway with its
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principal metabolites, 
and methionine. By donation of the methylgroup, AdoMet 
is converted into AdoHcy, which us hydrolyzed into homo*
into cysteine in the transsulfuration pathway or remeth 
ylated into methionine. Two enzymes catalyze the re meth 
ylation of homocysteine. sterne met
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transferase {EC 2.1.1.5) uses betaine as methyldonor and is 
active only in the liver [11]. 5-Methyltetrahydrofolate ho­
mocysteine methyltransferase (EC 2.1.1.13) is active in 
many, if not all, tissues and uses 5-methyltetrahydrofolate 
as methyldonor [11]. Next to its role in protein synthesis, 
the essential aminoacid methionine can be activated as 
methyldonor by formation of AdoMet, using ATP as co­
substrate [11].
Recently, we reported the effect of 6MP on the principal 
transmethylation metabolites it vitro [12]. Incubation of 
Molt-F4 human malignant ALL lymphoblasts with 6MP 
resulted in a decrease in AdoMet and the AdoMet/AdoHcy 
ratio, in an increase in AdoHcy and methionine in these 
cells, and a decreased release of homocysteine into the cul­
ture medium [12]. The decreased AdoMet/AdoHcy ratio 
could, theoretically, be caused by a depletion of the 
AdoMet pool due to its consumption for thiopurine meth- 
ylation. However, similar effects on AdoMet, AdoHcy, me­
thionine, and homocysteine were demonstrated after incu­
bation of these cells with MeMPR, which already contains 
a methylgroup. Thus, the effects of 6MP and MeMPR on
these transmethylation metabolites were ascribed to the 
reduced conversion of methionine into AdoMet, due to 
ATPdepletion produced by MetIMP [12]. More recently, we 
observed that incubation of Molt-F4 lymphoblasts with
6MP or MeMPR resulted in a decrease in the incorporation 
of [14C] from [14C]-methionine into total DNA [13], sug­
gesting that thiopurines can influence DNA méthylation in 
vitro.
It is well known that quantitative large amounts of 6MP 
are methylated in vivo. In RBC of ALL patients treated 
daily with oral 6MP (75 mg • m-2), the median methylthio- 
inosine nucleotide levels were 4-36 nm ol/8* 10 RBC 
(range 0.25-22.5), compared to the much lower median 
thioguanine nucleotides levels of 335 pmol/8*108 RBC 
(range 144-1263) [14]. Methylthioinosine nucleotide lev­
els were even higher in RBC [15] and mononuclear cells 
[16], compared to those of thioguanine, when high doses of 
6MP were administered intravenously. Influences of 6MP 
on the transmethylation metabolites in vivo have not been 
investigated up to now.
In the present study, we investigated influences of high- 
dose 6MP infusions on méthylation capacity in vivo. In the 
consolidation treatment of the Dutch Childhood Leukemia 
Study Group (DCLSG-ALL-8 protocol) ALL patients are
randomized for high-dose intravenous 6MP or low-dose oral 
6MP. We investigated the oral 6MP group as the control 
group for the intravenous 6MP group, because both groups 
also received methotrexate (MTX) infusions. This inhibits 
dihydrofolate reductase (EC 1.5.1.3), causing a depletion of 
active tetrahydrofolate compounds (Scheme 2). Thus, it 
indirectly inhibits folate-dependent reactions, such as re- 
methylation of homocysteine into methionine, purine de 
novo synthesis, and thymidylate synthesis [17].
The amounts of 6MP methylated in vivo were investi­
gated by measurement of the methylated metabolites of 
6MP in RBC, plasma, and urine. The influence of the in­
fusions on the transmethylation metabolites was investi­
gated by measurement of methionine and homocysteine in 
plasma and AdoMet, AdoHcy, and purine nucleotides in- 
tracellularly. Lymphoblasts were not available for investi-
compound methylated
compound
THF (leucovorin)
SCHEME 2. The transmethylation pathway. 1, thiopurine- 
methyltransferase and other AdoMet-dependent m ethyl 
transferases; 2, dihydrofolate reductase; 3, 5-methyl-te 
trahydrofolate homocysteine methyltransferase: DHF/THF
di/tetra hydrofolate. ’
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gation, because the patients were in complete remission.
We used RBC, because TPMT activity in RBC correlates 
with that in lymphoblasts and other tissues [4-7]. RBC can 
synthesize 5-phosphoribosyl-l-pyrophosphate [18], an es­
sential cofactor for the conversion of 6MP into tIMP, but 
do not manifest an active purine de novo synthesis, as ALL 
lymphoblasts do [19].
METHODS
Ten children with ALL were treated in our center accord­
ing to the DCLSG-ALL-8 protocol with a consolidation
(5 g • m-2 in 24 hr, 4 courses inMTX
8 weeks). Leucovorin rescue (Scheme 2) was started at 36 
hr after the MTX infusion was begun and continued every 
6 hr until MTX plasma levels were less than 0.25 |xM. Five 
of the 10 patients were randomized for oral 6MP (25 
• m 2 daily for 8 weeks, starting 7 days before the first 
MTX course) and the other 5 received 6MP intravenously
(1300 mg • m“2 in 24 hr, from 24 until 48 hr after MTX
infusion, 4 courses in 8 weeks). Patient or parental approval 
was obtained according to the ethical guidelines of our hos-
RESULTS
Methylated Metabolites of 
6MPin Plasma, RBC, and Urine
Figure 1 shows the mean levels of the methylated m etabo­
lites of 6MP in plasma of the intravenous 6MP group. 
Steady state levels of 6MP and MeMP were 11.6 (sem 1.6) 
and 0.6 (sem 0.1) |xM, respectively. MeM80HP reached 
levels of 2.6 (sem 0.5) |xM during the 6MP infusion. U pon  
its termination, MeMP and MeM80HP were rapidly 
cleared from plasma. MeMPR increased slowly during the 
6MP infusion and reached levels of 0.3 (sem 0.05) |xM 24 
hr after its termination. Methylthioxanthine and methylth- 
iouric acid were not detectable in plasma of these patients.
Figure 2 shows the levels of MetIMP, MetIDP, and Me- 
tlTP in RBC of patients in the intravenous 6MP group. 
These levels increased during and after the infusion. A t  72 
hr, the mean levels of MetIMP were 3.1 (sem 0.6), of 
MetIDP 0.8 (sem 0.3), and of MetlTP 1.4 (sem 0.4) nm ol/
10 RBC. At the start of the next course, the m ean
MaMSOHP e MeMP Tk MeMPR
Blood was sampled during the 4 courses of all patients in 
the oral and intravenous group, before and 24, 28, 48, 52 
and 72 hr after the MTX infusion was begun. Plasma and 
RBC were isolated as described [20]. RBC transfusions, an
essential part of the supportive treatment during the inten­
sive consolidation treatment, were given between the 
courses, but never during a course. Dithiothreitol was added 
to plasma, RBC, and urine to prevent oxidation of the thiol 
groups [20]. Urine was collected during the 24 hr of the 
6MP infusion as well as during the next 24 hr, either as a 
pooled 24'hr sample or as fractionated samples of approx­
imately 6 hr. In children with nappies, we collected one
at the end of the infusion. The methylated 
metabolites of 6MP and the purine nucleotides were ex­
tracted and measured with HPLC using ultraviolet absor­
bance. Detection limits for the methylated metabolites in 
plasma were 20-50 nM and for MetIMP 11 pmol per 100 
(xL injection [20j. A previously indeterminate metabolite of 
6MP [20] was identified as MeM8QHP. It was measured as
>ther methylthiopurine metabolites and eluted at 30
urine
c
min [20]. Total homocysteine was measured with HPLC 
after reduction with sodium borohydride and derivatization 
with monobromobimane [21]. Methionine was measured as 
described [12]. AdoMet and AdoHcy were extracted from
200 fxL RBC (2-3.1012 RBC/L 0.9% (w/v) saline with 0.1% 
(w/v) dithiotreitol) and 200 |xL water with 40 |xL 55%
trichloroacetic acid and kept on ice for 10 min. After cen-j 
trifugation, 300 |xL of the supernatants were washed 3 times 
with 2 volumes of peroxide-free diethylether to remove the 
trichloroacetic acid. The samples were flushed with nitro­
gen to a final volume of 150 |xL. AdoMet and AdoHcy were
measured with HPLC [12] at 248, 254, and 260 nm.
hr
FIG. 1. Methylated metabolites of 6MP in plasma of th e  in­
travenous 6MP group Patients were treated with an MTX  
infusion from 0-24 hr and a 6MP infusion from 24—4 8  hr. 
The means of all courses and all patients are indicated by 
the markers, the error bars indicate the SEM.
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FIG. 2, Methylated metabolites of 6MP in RBC of the intra­
venous 6MP group. Patients were treated with an MTX 
infusion from 0-24 hr and a 6MP infusion from 24-48 hr. 
The means of all courses and all patients are indicated by 
the markers, the error bars indicate the SEM.
MetIMP levels were decreased to less than one tenth of the 
level at 72 hr of the previous course, whereas those of 
MetIDP were one half and of MetlTP one third. Four chil­
dren. each received one RBC transfusion between the 
courses. After this, the methylthioinosine nucleotide levels 
at the start of the next course were in the same range or 
higher, compared to those of the previous course. Interin- 
dividual variation coefficients of 6MP and the methylated 
metabolites in plasma and RBC were between 30 and 50%.
In urine 6MP, thioxanthine, and thiouric acid were the 
main metabolites. MeMP, MeM80HP, methylthio-
xanthine, and methylthiouric acid were not detectable 
in urine. MeMPR accounted for less than 2% of all ex­
creted metabolites of 6MP in urine during the 6MP infu­
sion.
Urine of the oral group was not collected. In plasma and
RBC samples of the oral 6MP group at 0, 24, 28,48, 52, and 
72 hr, none of the metabolites of 6MP was detectable. Oral 
6MP (25 mg • m~2) was given at 7 a.m., whereas blood was 
sampled at 1 or 5 p.m..
and intravenous 6MP group were in the normal range [22] 
and remained constant during the MTX and 6MP infusions 
of all courses. ATP levels were 13.1 (sem 0.9) nmol/108
RBC.
AdoMet and AdoHcy in RBC
AdoMet levels were analyzed in both groups, but were not 
detectable in any of the samples. The detection limit of
AdoMet in RBC is 20 pmoi/108 RBC. AdoHcy levels re­
mained constant in both groups. Mean AdoHcy levels were 
10.8 (sem 1.3) pmol/108 RBC in the intravenous and 9.1 
(sem 1.0) pmol/108 RBC in the oral group.
Methionine and Homocysteine in Plasma (Fig. 3)
In both groups, homocysteine levels increased by
130-250% upon administration of MTX and returned to
initial values after the start of leucovorin administration. 
Until 48 hr, there were no significant differences in homo­
cysteine levels between the groups but, at 52 and 72 hr, 
they were significantly lower in the intravenous group (t-
test, two-tailed, P = 0.03 and 0.002, respectively, df 34, all 
courses). Methionine levels decreased by 35-50% from 0 to
24 hr during all courses in the oral group and during the 
third and fourth course in the intravenous group. This de­
crease in methionine was not present during the first or 
second course in the intravenous group. After termination 
of the MTX infusion, methionine levels immediately re­
turned to initial levels in the oral group. In the intravenous 
group, methionine levels began to increase 4 hr after ter­
mination of the 6MP infusion and reached levels 137% 
above the initial levels at 72 hr. At 48 and 52 hr, methi­
onine levels were significantly higher in the oral group
(t-test, two-tailed, P = 0.05 and 0.05, respectively, df 33, all 
courses). At 0, 24, 28, and 72 hr, there were no significant 
differences. Methionine in unwashed RBC of 10 random
6MP
range of 60-200 pmol/108 RBC.
DISCUSSION
The importance of a balanced transmethylation pathway 
and its role in carcinogenesis and malignancy has been 
stressed by several studies and reviewed by Laird and Jae- 
nisch [23]. The méthylation pattern of DNA of human 
malignant cells is often characterized by widespread hypo- 
methylation, regional hypermethylation, and elevated ex­
pression levels of DNA methyltransferase activity. In ani­
mals, the administration of AdoMet was able to prevent or 
even reverse the development of tumors, whereas methyl- 
deficient diets were able to induce tumors, which is consis­
tent with the widespread hypomethylation in tumor DNA 
[23]. Recently, it was shown that DNA methyltransferase
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FIG. 3. Homocysteine (triangles) and methionine (circles) 
in plasma of the oral (solid lines) and intravenous (dotted 
lines) 6MP group. Patients in both groups were treated with 
a MTX infusion from 0-24 hr. Patients in the oral group 
received 6MP daily p.o., whereas patients in the intravenous 
6MP group received 6MP as an infusion from 24-48 hr. The 
means of all courses and all patients are indicated by the 
markers, the error bars indicate the SEM.
activity contributes substantially to the development of in­
testinal adenomas [24]. However, it remains unclear wheth­
er or not changes in the méthylation status (i.e. methionine 
metabolites, DNA methyltransferase activity, or DNA 
méthylation) play a causal role in carcinogenesis or are a 
property of the malignant cell. Even without this knowl­
edge, the méthylation status might be a target for chemo­
therapeutic agents. In line with this view, we recently
that incubation of Molt F4 lymphoblasts 
with 6MP resulted in changes in the concentrations of 
transmethylation metabolites [12] and in DNA méthyl­
ation [13].
The present study is the first to investigate the influence 
of high-dose 6MP on transmethylation metabolites in vivo. 
Large amounts of methylated thiopurines were detectable 
in plasma and RBC after high-dose intravenous 6MP, with 
interpatient variabilities of 30-50% (Fig. 1, 2). TPMT ac­
tivities in peripheral mononuclear cells ranged from 4.6- 
16.1 IU/109 cells in the present group, demonstrating in­
termediate and high activity [25]. The genetic polymor­
phism of TPMT may be partially responsible for the 
interpatient variability. We could not demonstrate a cor­
relation between TPMT activity and (methyl)thiopurines, 
because a high percentage of TPMT assays in mononuclear 
cells fail due to the lack of cells in leukopenic patients as 
well as other enzymes involved in thiopurine metabolism
(Scheme 1) [25]. Measurement of TPMT in RBC would not 
be informative because RBC are transfused during the in­
duction and consolidation treatment. The presence of 
methylated metabolites of 6MP in urine was less pro­
nounced, compared to that in plasma and RBC. The ab­
sence of MeMP and MeMBOHP in urine might be the 
result of oxidation [26] or glucuronidation [27] of these 
compounds or of désulfuration of the drug [27]. Methyl- 
thioxanthine and methylthiouric acid were not detectable 
in plasma or urine, which is in concordance with the results 
obtained from patients treated with 6MP and MeMP [28] 
and with in vitro data demonstrating that thioxanthine and 
thiouric acid are inhibitors of TPMT [29].
In the oral group, 6MP and its metabolites were not 
detectable in plasma nor RBC. Blood sampling was timed 
after the start of MTX, as in the intravenous group, and not 
after 6MP intake. Detection of mono-, di- and triphosphate 
nucleotides in RBC requires higher intracellular concentra­
tions of methylthioinosine nucleotides compared to mea­
surement of MeMP after hydrolysis of the nucleotides. The 
administered dose (25 mg • m daily for 8 weeks) was one
third of the administered daily during 1.5-2-year
maintenance therapy of ALL [14], too low for detection of 
methylthio inosine nucleotides in the oral group.
The high levels of methylthioinosine nucleotides in RBC 
in the intravenous group indicate that the transmethylation 
rate and, thus, the rate of AdoMet synthesis must have 
been high in RBC. AdoMet levels were below the detection 
limit in all RBC samples, but the increasing levels of me­
thylthioinosine nucleotides in RBC after termination of the 
infusion indicate that sufficient AdoMet was available for 
this méthylation reaction. In RBC of healthy controls, 
mean AdoMet levels were 3.5-5.2 (xmol/L packed fresh
RBC (30-32) (±10*1012 RBC/1 packed cells). Roughly,
| | i
these levels are just above our detection limit (20 pmol/10
i j
RBC). AdoHcy levels were approximately 10 pmol/10 
RBC and remained constant during the MTX and 6MP 
infusions. In one study, mean AdoHcy levels were one third 
of those of AdoMet in fresh RBC of healthy subjects [31] 
whereas, in our study, AdoMet levels were lower than Ado- 
Hey levels. We used stored RBC from patients treated for 
leukemia, which may have influenced the difference. We 
are not aware of a study having been conducted on AdoMet 
and AdoHcy levels in RBC under similar conditions.
Changes in homocysteine and methionine levels in 
plasma were observed in both groups. The increase in ho­
mocysteine and the decrease in methionine in plasma after 
the start of MTX administration could be ascribed to the 
decreased remethylation of homocysteine, itself the result
1170 C. W. Keuzenkamp-Jansen et al.
of the decreased availability of tetrahydrofolate derivatives 
due to inhibition of dihydrofolate reductase by MTX 
(Scheme 2). These changes have also been demonstrated 
by other [33-35]. A decrease in methionine levels was not 
detectable during the first two courses in the intravenous 
group, probably because we did not measure between 0 and
24 hr when the nadir was reached [35].
After termination of the MTX infusion, methionine and 
homocysteine levels were different for the two groups. 
Upon leucovorin administration, homocysteine levels de- 
creased in both groups, but decreased to significantly lower 
levels at 52 and 72 hr in the intravenous 6MP group. Me-
thionine levels increased immediately to initial levels after 
termination of the MTX infusion in the oral group, but 
remained low in the intravenous group during the 6MP 
infusion, after which they rebounded above initial levels. 
Because leucovorin, which increases methylation of homo­
cysteine into methionine, was administered 12 hr after the 
start of the 6MP infusion, the pure effect of high-dose 6MP 
on the transmethylation metabolites may be masked. The 
delay in the recovery of methionine after termination of the 
MTX infusion in the intravenous group may be the result of 
the high consumption of methionine for methylation of 
thiopurines.
Thus, our study in children with ALL in remission shows 
an effect of high-dose 6MP in plasma (i.e. a delay in the 
recovery of the decrease in methionine due to MTX). This 
study does not show evidence for an effect of high-dose 
6MP in RBC. This does not exclude the possibility that 
high-dose 6MP influences the transmethylation metabo­
lites in the lymphoblasts. However, as all patients were in 
complete remission during the consolidation treatment, 
lymphoblasts are not available. It would be worthwhile to 
investigate the effects of high-dose 6MP alone on the trans­
methylation pathway in the lymphoblasts immediately after 
diagnosis, which will probably be done in a window phase
of the next DCLSG study (ALL-9).
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